Introduction
G protein-coupled receptors (GPCRs) represent the largest class of cell surface receptors in the human genome, and are the primary target for approximately 30% of currently marketed (mostly small molecule) drugs [1, 2] . In recent years, however, there has been renewed interest in the potential development of therapeutic antibodies for this superfamily of cell surface receptors [3] [4] [5] . GPCRs consist of seven transmembrane-spanning a-helices (TM1-7), an extracellular N-terminus, an intracellular C-terminus, three extracellular loops (ECL1-3) and three intracellular loops (ICL1-3). The extracellular regions have the greatest diversity between different GPCRs [6] , even between closely related receptor subtypes such as the b 1 -and b 2 -adrenoceptors, and are attractive immunogenic targets [7] [8] [9] .
Epitope mapping and functional characterisation of GPCRs have demonstrated that a major immunogenic epitope is located on the Abbreviations: ATCM, allosteric ternary complex model; CHO, Chinese hamster ovary; CRE, cAMP response element; ECL, extracellular loop; HEK, human embryonic kidney; mAb, monoclonal antibody; SPAP, secreted placental alkaline phosphatase; StaR, stabilised receptor. second extracellular loop (ECL2) [10] [11] [12] . The structure of the ECL2 varies greatly between different GPCRs [7, 8, [13] [14] [15] [16] . It has been suggested to have roles in ligand recognition and selectivity for the b-adrenoceptors [17] [18] [19] , and has recently been implicated as a site of allosteric modulation for the adenosine A 1 receptor [20, 21] . The structure and position of the ECL2 is critical for receptor conformation and activation [22, 23] . Most interestingly, pathogenic antibodies have been identified, that can activate the b 1 -adrenoceptor by binding to ECL2, and lead to the development of a form of cardiomyopathy [10, 24] . Furthermore, different populations of antibodies directed at ECL2, isolated from patients, have been reported to stabilise different b 1 -adrenoceptor conformations, affecting agonist-driven activation and subsequent receptor desensitisation [25] .
Recent advances in crystallisation techniques for GPCRs (such as thermo-stabilised receptors: StaRs; [26, 27] ) have facilitated the large-scale purification of stable GPCRs in a conformation appropriate for both X-ray crystallography and their use as antigens for monoclonal antibody generation. Previously, Hutchings et al. [28] characterised a series of monoclonal antibodies (mAbs) that were raised against the thermo-stabilised turkey b 1 -adrenoceptor (b 1 AR-m23 StaR) [8] . These were found to bind to the b 1 AR-m23 StaR [8] and were able to produce small cAMP agonist responses in CHO cells transiently expressing the wildtype turkey b 1 -adrenoceptor (tb 1 -AR) [28] . One mAb (mAb3) was suggested to bind to an allosteric site on the tb 1 -AR, since there were indications of non-competitive antagonism with the orthosteric antagonist dihydroalprenolol [28] . The aim of this study was to investigate in more detail the pharmacology of mAb3 at the human and turkey b 1 -adrenoceptors in cell lines stably expressing each of these receptors. OR, USA). Fugene HD transfection reagent and furimazine were from Promega (Southampton, UK). Purified turkey and human ECL2 peptides were obtained from Cambridge Research Biochemicals (Cambridge, UK). All other reagents were from Sigma-Aldrich (Gillingham, UK).
Materials and methods

Materials
Constructs, cell lines and cell culture
To create the NL-tb6-m23 construct, NanoLuc (NL) was ligated into pcDNA3.1 containing the 5-HT 3A membrane localisation signal sequence (sig) as previously described [29] . The tb6-m23 receptor was then ligated to the C-terminus of NL from pcDNA3.1 with tb6-m23 [30] using BamHI and XbaI restriction enzymes. Mutagenic primers were then used to mutate the start codon of the tb6-m23 receptor (Met into Leu) to create a fusion protein with a Gly-Ser linker between the NL open reading frame and the tb6-m23 open reading frame. Finally, to ensure there were no mismatches in the plasmid potentially introduced from the mutagenesis reaction, the NL-tb6-m23 fusion protein was ligated into a fresh pcDNA3.1 plasmid using KpnI and XbaI restriction enzymes. The ECL2 point mutations for tb6-m23 were generated using QuickChange mutagenesis protocol (Stratagene, La Jolla, CA, USA) see Table 1 for primer sequences. The triple ECL2 mutant of D186S, P187D, Q188E was generated in two stages by sequential point mutations. First, the single D186S mutation was made as described above. Then, the triple mutant of D186S + P187D + Q188E was made with primers in Table 1 using the single D186S mutant sequence as the PCR template. All mutation sequences were confirmed by DNA sequencing using the School of Life Sciences Sequencing Facility at the University of Nottingham. Following successful mutagenesis, the mutant tb6-m23 receptor cDNA was digested with BamHI/XhoI and subcloned into native pcDNA3.1(+) containing a neomycin selection marker.
Chinese hamster ovary (CHO-K1) cells stably expressing either the human b 1 -adrenoceptor, the C-terminally truncated turkey badrenoceptor (tbtrunc; [31] ), or an N-terminally truncated tbtrunc with the m23 thermostabilising mutations (tb6-m23; [30, 31] ) were used in this study. In addition to the b-adrenoceptor, these CHO-K1 cells also stably expressed a cyclic AMP response element-secreted placental alkaline phosphatase (CRE-SPAP) reporter gene. HEK 293 cells transiently expressing NL-tb6-m23 were also used in this study. Cells were cultured in Dulbecco's modified Eagle's medium nutrient mix F12 (DMEM/F12, CHO cells) or Dulbecco's modified Eagle's medium (DMEM, HEK cells) containing 10% foetal calf serum and 2 mM L-glutamine in a 37°C humidified 95% air/5% CO 2 atmosphere. All CHO cell lines were kindly provided by Prof. Jill Baker. 
Enzyme-linked Immunosorbant assays (ELISAs)
Purified b 1 AR-m23 StaR, [8] was immobilised through the capture of the C-terminal 6-His tag to Ni + -coated Nunc Immobilizer 96-well plates. Each well was coated with PBS containing 0.5 lg/ ml purified protein solubilised in 0.1% DM (n-Decyl-bmaltopyranoside) and 100 lM alprenolol. Each well was blocked with PBS containing 0.1% DM, 100 lM alprenolol and 3% milk powder (blocking solution) for 1 h at room temperature. During this stage, dilutions of mAb3 were incubated with 250 lg/ml or 500 lg/ml ECL2 peptide in blocking solution for 1 h (Human ECL2 peptide: MHWWRAESDEARRCYNDPKCCDFVTN, Turkey ECL2 peptide: MHWWRDEDPQALKCYQDPGCCDFVTN; Cambridge Research Biochemicals, Cambridge, UK). Following this, each well was incubated with the mAb3/ECL2 blocking solution for 1 h. Wells were then washed with 3 Â 200 ll of PBS with 0.05% Tween-20, 0.1% DM and 100 lM alprenolol. A goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody (1:1000) was added to each well in 100 ll PBS with 0.05% tween-20, 0.1% DM and 100 lM alprenolol. Bound antibody was detected using the 3,3 0 ,5,5 0 -Tetra methylbenzidine (TMB) liquid substrate system (Sigma-Aldrich, Gillingham, UK). The absorbance was measured at 655 nm using a POLARstar Omega plate reader (BMG Labtech, Germany).
Wide-field microscopy
Wide-field microscopy was performed using an ImageXpress Micro XLS System microscope with a Plan Fluor ELWD 20Â objective and a 4.66 megapixel CMOS camera for the acquisition of images. CHO cells were grown to confluence in sterile blacksided tissue culture-treated 96-well plates. For ECL2 competition assays, cells were fixed with 3% paraformaldehyde in PBS for 15 min at room temperature. Cells were washed three times with ice-cold PBS and blocked with 0.5% bovine serum albumin (BSA) in PBS (blocking solution) for 30 min on a shaker (60 rpm) at 4°C
. During this period, 66 nM mAb3 was incubated with the purified turkey or human ECL2 peptide in the blocking solution. The blocking solution was removed from the cells and replaced with the mAb3/ECL2 solution for 1 h at room temperature.
Cells were then washed three times with ice-cold PBS and then incubated with the secondary antibody (goat anti-mouseRhodamine Red IgG, 1:500 in 10% goat serum with PBS) for 1 h in the dark at room temperature. This was then washed with three ice-cold PBS washes before cells were stained with 2 lg/ml Hoechst 33342 stain in PBS for 20 min. Three cold PBS washes removed any excess stain and the plates were stored at 4°C in the dark overnight before being imaged on the ImageXpress Micro XLS System microscope (Molecular Devices, Wokingham, UK). Each site was imaged twice, once with the ZPS DAPI filter (ex 405 nm) to capture the Hoechst 33342 nuclear stain, and again with the ZPS CY5/TRITC filter (ex 560 nm) to capture the Rhodamine from the secondary antibody. 
NanoBRET ligand binding assay
Saturation-and competition-binding assays were performed on transiently transfected HEK 293 NL-tb6-m23 cells. White 96-well microplates were coated with 50 ml poly-D-lysine (10 mg/ml in PBS) for 30 min and then washed with 100 ml PBS. Following this, 5 ml transfection mix (Optimem with 100 ng NL-tb6-m23 plasmid DNA and 50 ml/ml Fugene HD transfection reagent) was added to each well. 100 ml DMEM with cells in suspension (20,000 cells/well) was then seeded onto these wells containing the transfection mix to ensure complete mixing of the transfection mix and cells. After 24 h, the medium was removed from each well and replaced with HEPES-buffered saline solution (HBSS; 145 mM NaCL, 5 mM KCl, 1.7 mM CaCl 2 , 1 mM MgSO 4 , 10 mM HEPES, 2 mM sodium pyruvate, 1.5 mM NaHCO 3 , 10 mM D-glucose, pH 7.45) with the relevant concentration of fluorescent ligand and, if necessary, competing ligand or mAb3. Nonspecific binding was determined with 10 mM propranolol. Cells were then incubated for 1 h at 37°C in the dark. The NanoLuc substrate furimazine (Promega, Southampton, UK) was then added to each well at a final concentration of 10 mM and allowed to equilibrate for 5 min prior to reading. Luminescence signals were measured at two different wavelengths using a PHERAstar FS plate reader (BMG Labtech, UK) at room temperature. The filtered light from each well was simultaneously measured using 460 nm (80-nm bandpass) and >610 nm longpass filters. The resulting raw BRET ratio was calculated by dividing the >610 nm emission by the 460 nm emission.
For saturation NanoBRET experiments with mAb3, HEK cells transiently expressing NL-tb6-m23 were fixed with 3% paraformaldehyde in PBS for 15 min at room temperature. Cells were then washed three times with PBS before being incubated with 100 ml PBS containing mAb3 in a concentration range of 1-250 nM for 1 h at 37°C. The cells were then washed three times with PBS and then incubated with the secondary antibody (goat anti-mouse-Rhodamine Red IgG, 1:500 in 10% goat serum with PBS) for 1 h in the dark at room temperature. Finally, furimazine was added and the BRET was measured as described above. other nucleotides was then performed as previously described in [34] .
CRE-mediated gene transcription (SPAP)
CHO cells stably expressing the CRE-SPAP reporter gene and either human or turkey b-adrenoceptors were grown to confluence in sterile, clear, tissue culture-treated 96-well plates and serum-starved 24 h before experimentation in serum-free media. On the day of experimentation, media were aspirated from each well and replaced with 90 ll fresh serum-free media. Ligands were then added (in triplicate) in 10 ll serum-free media and the plate was incubated at 37°C in a humidified 95% air/5% CO 2 atmosphere for 5 h. 10 lM isoprenaline was used to determine the maximal response in each plate for each experiment. Media and compounds were then aspirated and replaced with 40 ll serum-free media. Plates were incubated for a further hour at 37°C in the same atmosphere. The plates were then heated to 65°C for 25 min to destroy any endogenous alkaline phosphatases. After allowing them to cool to room temperature, 100 ll diethanolamine buffer (pH 9.85) containing p-nitrophenol phosphate (PNPP) was added to each well and the plates incubated at 37°C for 20 min in air. CRE-mediated SPAP reporter activity was quantified by the colour change resulting from the hydrolysis of PNPP. This was measured as the optical density at 405 nm using a Dynatech Laboratories MRX plate reader.
Data analysis
Data were analysed using Prism 6 software (GraphPad, San Diego, USA).
Saturation radioligand-binding curves were fitted simultaneously for total ([ 3 H]-CGP 12177 alone) and non-specific binding (in the presence of 10 mM propranolol) using the following equation: The affinity of mAb3 was calculated from radioligand binding data following the allosteric ternary complex model previously described [35] :
where IC 50 is the concentration of allosteric modulator (B) required for 50% inhibition of specific binding of a fixed concentration [A] of radioligand, K A and K B are the dissociation constants for the radioligand and allosteric modulator respectively, and a is the cooperativity factor between the allosteric modulator and radioligand. Specific binding curves for CGP 12177 or mAb3 were fit to the following equation:
where B max is the maximal specific binding, [B] the concentration of fluorescent ligand or mAb3 (nM) and K D the equilibrium dissociation constant (nM). Agonist response curves were best described by a one-site sigmoidal concentration response curve using the following equation:
where E max is the maximum system response, [A] is the agonist concentration, and EC 50 is the concentration of agonist required to produce 50% of the maximal response. The affinity of mAb3 was estimated from [ 3 H]-cAMP accumulation and CRE-SPAP reporter gene assays using the model described in [36] . The relative activity (RA) was first calculated for isoprenaline in the presence of each concentration of mAb3 using the following equation:
where RA is the relative activity of the agonist in the presence of the allosteric modulator, E 0 max and EC 0 50 denote the E max and EC 50 values of the agonist in the absence of the allosteric modulator, and E max and EC 50 are the values measured of the agonist in the presence of the allosteric modulator. This analysis was performed with the constraint that the Hill slopes were equal to a value of 1.
To obtain an estimate for the affinity of mAb3, the RA obtained at each concentration of mAb3 was plotted against the concentration of mAb3 (B). Nonlinear regression analysis of these data was performed using the following equation in Prism 6:
where K B is the dissociation constant of mAb3 (B), and c is the product of the effects the mAb3 has on the intrinsic efficacy and affinity of the agonist-receptor complex.
The 
Results
MAb3 binding to ECL2 of the purified turkey b 1 AR-m23 StaR receptor
The crystal structure of the b 1 -adrenoceptor was first solved using a thermo-stabilised turkey b 1 -AR (b 1 AR-m23 StaR) [8] . This construct and the resulting protein produced were used to generate a panel of monoclonal antibodies using a combination of cDNA immunization and protein boosting [28] . One of these antibodies (mAb3) was demonstrated to bind to the b 1 AR-m23 StaR expressed in HEK cells. Using purified proteins, the epitope of mAb3 was suggested to be located on the second extracellular loop (ECL2) of the turkey b 1 -AR [28] . Here, we investigated the effect of a purified ECL2 peptide on the binding of mAb3 to the b 1 AR-m23 StaR. Pre-incubation of mAb3 with purified turkey b 1 -AR ECL2 (Tk ECL2) significantly reduced the specific binding of mAb3 to the purified b 1 AR-m23 StaR in a concentrationdependent manner (Fig. 1a , p < 0.05, one way ANOVA). In contrast, pre-incubation of mAb3 with purified human b 1 -AR ECL2 (Hu ECL2) did not significantly attenuate binding to b 1 AR-m23 StaR, but rather produced a significant increase in specific binding at the highest concentrations of mAb3 used (33 nM and 6.6 nM; Fig. 1b , p < 0.05, one way ANOVA).
Immunohistochemistry of mAb3 binding to CHO cells expressing b 1 -ARs
With mAb3 showing strong binding to the purified b 1 AR-m23 StaR, we next investigated the binding capabilities of mAb3 in CHO cells. Two CHO cell lines stably expressing the turkey b 1 -AR were used in this study: a low expressing cell line (tbtrunc, receptor expression level of 92 ± 14 fmol/mg protein, n = 8; determined in this study with [ 3 H]-CGP 12177 binding; [37] ), and a high expressing cell line (tb6-m23, receptor expression level 3128 ± 590 fmol/mg protein, n = 8; [30] ). In addition, a CHO cell line stably expressing the human b 1 -AR (hb 1 -AR) was used (receptor expression level 659 ± 77 fmol/mg protein, n = 6; [38] ).
The specific binding of mAb3 to CHO cells expressing b 1 -ARs was visualised using immunocytochemistry (Fig. 2) . MAb3 was able to specifically label the turkey b 1 -AR stably expressed on the surface of intact CHO cells (Fig. 2a) . CHO cells stably expressing the human b 1 -AR (hb 1 -AR) did not display any binding of mAb3 (Fig. 2a) . Quantitative analysis on these images calculated the average fluorescence intensity of cells as a measure of mAb3 binding. The average cell intensity of the secondary antibody-only controls was subtracted from the intensities of cells treated with mAb3 to give a measure of the specific intensity of mAb3 binding (corrected cell intensity). CHO cells expressing the tbtrunc and tb6-m23 receptors had significantly higher average cell intensities than the secondary antibody-only control (corrected average cell intensities tb6-m23 55.0 ± 8.5 greyscale units; tbtrunc 15.3 ± 2.9 greyscale units; n = 4, Fig. 2b , p < 0.05, paired t-test). The relative degree of mAb3 labelling was consistent with the relative receptor expression levels calculated using radioligand binding. This analysis also confirmed there was no specific binding of mAb3 to the hb 1 -AR, since the average cell intensity did not significantly differ from the secondary antibody-only control (corrected cell intensity hb 1 -AR 2.3 ± 1.1 greyscale units; n = 4, Fig. 2b , p > 0.05, paired ttest).
The specific binding of mAb3 to the turkey receptors was displaced by addition of either 250 lg/ml or 500 lg/ml purified Tk ECL2 peptide (Fig. 2c, d ). Pre-incubation of mAb3 with Tk ECL2 at both concentrations reduced specific binding to the tbtrunc receptor to circa 50% that of mAb3 alone (250 lg/ml Tk ECL2, 49.0 ± 9.9%; 500 lg/ml Tk ECL2, 47.9 ± 5.3%, respectively; n = 4). This effect was more pronounced in cells expressing the tb6-m23 receptor. In these cells, the addition of Tk ECL2 resulted in only 31.2 ± 10.6% (250 lg/ml Tk ECL2) and 21.7 ± 6.6% (500 lg/ml Tk ECL2)
of the specific binding elicited by mAb3 alone (n = 4, Fig. 2d ). Interestingly, pre-incubation of mAb3 with Hu ECL2 peptide did not result in a significant reduction of mAb3 binding to the tbtrunc or tb6-m23 receptors (500 mg/ml 76.8 ± 32.6% tbtrunc; 88.0 ± 5.6% tb6-m23, Fig. 2e , p > 0.05 paired t-test).
3.3. Effect of mAb3 on the specific binding of [ (Fig. 3a and b) . However, the maximal inhibition of specific [ 3 H]-CGP 12177 binding by mAb3 was lower than that produced by the orthosteric antagonist CGP 20712A in the same experiments (Fig. 3a and b, Table 2 ). Taken together with the fact that the epitope of mAb3 was thought to be on ECL2 [28] , these data suggested that mAb3 may be acting allosterically with respect to the known small molecule orthosteric binding site on the turkey b 1 -ARs. Statistical comparison was performed to ascertain whether the allosteric ternary complex model (ATCM, [35] ) was the best model to describe these data. For both receptors, globally analysing the data with the ATCM provided a better description of the data than the standard three-parameter inhibition model (p < 0.001, tbtrunc; p < 0.05 tb6-m23, partial F test). Application of the ATCM provided estimates for the affinity of mAb3 at the tbtrunc and tb6-m23 receptors, as well as an estimate for the cooperativity factor (a) between mAb3 and [ 3 H]-CGP 12177 (Table 2) . From these analyses, mAb3 had similar affinities at the tbtrunc (log K B À7.56 ± 0.08) and at the tb6-m23 (log K B À7.70 ± 0.09). The estimated a values at both tbtrunc and tb6-m23 suggested a high degree of negative cooperativity between mAb3 and [ 3 H]-CGP 12177 at these receptors. There was no evidence of mAb3 binding to the hb 1 -AR (Fig. 3c) , which was consistent with the data obtained with the purified Hu ECL2 peptide.
To investigate further the role that the ECL2 plays in the binding of mAb3 to the full length receptor, a mutant tb6-m23 receptor construct was made whereby the Tk ECL2 was mutated to the Hu ECL2 sequence (tb6-m23-hECL2), and this construct was transiently expressed in CHO cells. Specific binding of [ 3 H]-CGP 12177 was observed at this receptor (K D 7.85 ± 0.88 nM, B max 2857 ± 262 fmol/mg protein; n = 4), demonstrating that the resulting receptor protein was expressed on the plasma membrane. Increasing concentrations of propranolol were able to inhibit the specific binding of [ 3 H]-CGP 12177 (log K i propranolol À6.73 ± 0.08; n = 5). However, as with the hb 1 -AR, mAb3 could not bind to the tb6-m23-hECL2 receptor (Fig. 3d) , further suggesting that the epitope of mAb3 existed entirely within the turkey ECL2.
The turkey ECL2 is 26 amino acids in length and shares 70% identity with the human ECL2. The eight residues that differ between the two species have been highlighted on the recently solved b 1 AR-m23 StaR crystal structure [39] (Fig. 4a-c) . The majority of these residues exist on the extracellular surface of the loop (Fig. 4a) , with side chains facing away from the ligand-binding pocket, projecting into the extracellular space (Fig. 4c) . In order to elucidate which residues were necessary for the binding of mAb3, a series of single point mutations were made, changing the turkey residue to the equivalent human residue. The eight mutations were as follows: D184A, D186S, P187D, Q188E, L190R, K191R, Q194N, and G197K (Fig. 4d) . Similar levels of specific binding of [ 3 H]-CGP 12177 were obtained with all mutant constructs (Table 1) . Single point mutations did not significantly affect the binding of mAb3 (Fig. 4e) , demonstrating that the epitope of mAb3 was not susceptible to the loss of a single residue. Given this fact, we then looked for clusters of amino acids that may be responsible for the mAb3 epitope. Residues D186, P187, Q188 were all located on the N-terminus of the a-helix in ECL2, and offered a potential target. Therefore, a chimeric tb6-m23 receptor containing the triple mutation D186S, P187D and Q188E was made (Table 1) . Interestingly, 1 mM mAb3 did not displace the specific binding of ( Fig. 5b) . The affinities of the orthosteric ligands determined here showed good agreement with previously published affinities [30] at the tb6-m23 receptor (isoprenaline log K i À5.03 ± 0.17, propranolol log K i À7.62 ± 0.15, CGP 20712A log K i À6.19 ± 0.14; n = 5 for each ligand in this study). The addition of 200 nM mAb3 resulted in a reduction in the specific binding of [ 3 H]-CGP 12177
(54.4 ± 1.1% of the specific binding in the absence of mAb3; n = 5). The addition of mAb3 did not significantly change the affinity of the antagonists propranolol or CGP 20712A (log K i values À7.96 ± 0.11, À6.64 ± 0.15, respectively; n = 5, p > 0.05 unpaired t-test). However, mAb3 appeared to produce a small but significant increase in the affinity of isoprenaline (log K i with 200 nM mAb3 À5.63 ± 0.10; n = 5, p < 0.05 compared to isoprenaline K i in absence of mAb3, unpaired t-test). Fitting the isoprenaline curves in Fig. 5b with different or shared IC 50 
Measuring mAb3 binding with NanoBRET in HEK293 cells
Proximity-based assays have provided a platform to monitor GPCR function and dimerization with great success [40, 41] . Recent advances in the brightness and stability of luciferases (e.g. NanoLuc, [42] ) have facilitated the use of bioluminescence resonance energy transfer (BRET) to monitor fluorescent ligand binding at GPCRs [29, 43] , and at a receptor tyrosine kinase [44] . Here we have utilised an N-terminal NanoLuc-tagged tb6-m23 receptor (NL-tb6-m23) expressed in HEK 293 cells to measure the binding of the fluorescent ligand CGP-12177-TMR [29, 43, 45] to the turkey b 1 -adrenoceptor expressed in HEK 293 cells (Fig. 6a) . CGP-12177-TMR showed clear specific binding to the NL-tb6-m23 receptor (Fig. 6b) . These data provided an estimate for the K D value of CGP-12177-TMR of 17.8 ± 4.0 nM (n = 4, Fig. 6b ). Incubation of CGP-12177-TMR with 20 nM mAb3 resulted in no significant effect on the affinity of CGP-12177-TMR (K D 31.1 ± 11.2; n = 4, paired t-test) or on the specific BRET ratio (87.7 ± 10.9% B max ; n = 4, paired t-test, Fig. 6b ) The addition of mAb3 at circa ten times K D (200 nM) resulted in a significant decrease in the specific BRET ratio (39.9 ± 9.3% B max ; n = 4, p < 0.05 paired t-test, Fig. 6b ) without any significant effect on the affinity of CGP-12177-TMR (K D with 200 nM mAb3 39.3 ± 11.4 nM; n = 4, p > 0.05 paired t-test).
NanoBRET was also used to quantify the direct binding of mAb3 to the NL-tb6-m23 receptor. In these experiments, mAb3 was allowed to bind the turkey ECL2, and was then treated with a fluorescently-conjugated secondary antibody. Upon luciferase substrate addition, the BRET between the luciferase and a rhodaminetagged secondary antibody (bound to mAb3) was then quantified (Fig. 7a) . The concentration of the secondary rhodamine-tagged antibody was kept constant across all conditions. Increasing concentrations of mAb3 resulted in an increase in the BRET ratio with a clear saturable component (Fig. 7b, c) . From these data, the affinity of mAb3 for the NL-tb6-m23 receptor in HEK cells was calculated to be 19.5 ± 4.7 nM (n = 4, Fig. 7c ).
Effect of mAb3 on b 1 -adrenoceptor-mediated G s signalling in stable cell lines
The tb 1 -AR couples to G s proteins, and therefore activation of the tb 1 -AR results in an increase in intracellular cAMP and activation of the protein kinase A signalling pathway [31, 37] . Here, we examined the potential for mAb3 to stimulate CRE-SPAP gene expression or [ Fig. 8a, c) . Similarly, 10 lM isoprenaline resulted in an increase in CRE-mediated SPAP production of 1.92 ± 0.07 (n = 33) and 2.04 ± 0.05 (n = 20) fold over basal for tbtrunc and tb6-m23 receptors, respectively (Fig. 8b, d ). MAb3 was unable to stimulate a change in [ 3 H]-cAMP or CRE-mediated SPAP production at either the tbtrunc or tb6-m23 receptors (Fig. 8, p To investigate whether mAb3 could antagonise isoprenalinestimulated responses, CHO cells stably expressing the tbtrunc or tb6-m23 receptors were stimulated with a range of concentrations of isoprenaline in the absence and presence of mAb3. Thirty minute pre-incubation with mAb3 was able to antagonise isoprenaline-mediated SPAP production at both the tbtrunc (Fig. 9a) and tb6-m23 (Fig. 9b) receptors in a concentrationdependent manner, resulting in a series of rightward shifts in the isoprenaline concentration-response curves and a reduction in E max (Table 3 ). Schild analysis gave Hill slopes of 0.91 ± 0.14 at the tbtrunc, and 0.68 ± 0.05 at the tb6-m23 receptors. The value obtained at the tb6-m23 receptor significantly differed from unity (p < 0.05, unpaired t-test comparing to unity), which suggested a non-competitive interaction between mAb3 and isoprenaline. It is clear from the radioligand binding studies (above) that mAb3 is acting allosterically on a sub-population/conformation of the b 1 AR. It is therefore likely that the antagonism of functional responses to isoprenaline by mAb3 is due to the gradual loss of this population of b 1 AR. For these reasons, functional data were also analysed using equations for an allosteric modulator derived from the functional model previously described [36, 46] . First, the relative activities of the isoprenaline concentration response curves in the presence and absence of mAb3 were calculated. Regression analysis of these relative activity values was then used to obtain an estimate for the affinity of mAb3. The resulting affinity of mAb3 was similar at the two turkey receptors (tbtrunc log K B À7.39 ± 0.11, n = 5; tb6-m23 log K B À7.50 ± 0.09, n = 5), which share good agreement with the affinity of mAb3 at these receptors measured with radioligand binding.
The same effect was observed when measuring [ 3 H]-cAMP accumulation in the high expressing tb6-m23 cell line in the presence of 1 mM IBMX. Increasing concentrations of mAb3 resulted in rightward shifts and reduction in E max in the concentrationresponse curves of isoprenaline after a five hour incubation (mAb3 log K B À7.75 ± 0.12, n = 5; Fig. 10a, Table 4 ). Interestingly, mAb3 did not have any effect on the partial agonist response of CGP 12177 ( Fig. 10b; Table 4 ).
MAb3 induces the dissociation of isoprenaline from the receptor
To investigate whether mAb3 binding to ECL2 was truly acting as (a) a negative allosteric regulator or (b) sterically interfering with the association or dissociation of ligands from the orthosteric binding site of the thermo-stabilised b 1 AR-m23 StaR, we investigated the effect of mAb3 on the kinetics of the intracellular cAMP response to isoprenaline. Isoprenaline (1lM) caused an increase in the intracellular [ 3 H]-cAMP concentration until equilibrium was reached after circa thirty minutes (Fig. 11a) . The addition of 10 lM CGP 20712A at equilibrium resulted in a sharp decrease in the concentration of intracellular [ 3 H]-cAMP that could be fitted to a one-phase exponential decay curve (Fig. 11a) . This was quantified by calculating an apparent rate constant for this effect (0.118 ± 0.012 min À1 ; n = 5) that reflects the rate for the dissociation of isoprenaline from the ligand binding pocket and the subsequent breakdown of [ 3 H]-cAMP. In contrast, the addition of serum-free media without any additional ligand did not result in any significant change in the intracellular levels of [ 3 H]-cAMP suggesting that there was no significant dissociation of isoprenaline from the receptor over this time period (p > 0.05, unpaired t-test comparing 1 lM isoprenaline with serum free media to that of 100% obtained in the presence of 1 lM isoprenaline alone; n = 5; data not shown).
1 lM mAb3 was able to cause a similar decrease in intracellular , n = 5) that was not significantly different from that obtained with 10 lM CGP 20712A alone (p > 0.05, unpaired t-test; Fig. 11b ). Cells were also treated with 1 lM mAb3 for the first sixteen minutes prior to the addition of 10 lM CGP 20712A. As can be seen in Fig. 11b , the initial reduction in intracellular [
3 H]-cAMP with mAb3 followed a similar time course to that previously seen with 1 lM mAb3. However, upon subsequent addition of 10 lM CGP 20712A in combination with 1 lM mAb3 
Discussion
MAb3 was originally generated against a thermo-stabilised b 1 AR-m23 StaR [28] . Here, we have demonstrated specific binding of mAb3 to the purified turkey b 1 AR-m23 StaR protein. Furthermore, binding of mAb3 to b 1 AR-m23 StaR protein was significantly inhibited by a turkey b 1 -AR ECL2 peptide confirming that the likely epitope for the antibody was in ECL2 as originally proposed by Hutchings et al. [28] . However, it was notable that the human ECL2 peptide did not attenuate mAb3 binding.
Two CHO cell lines expressing different mutant turkey b 1 -adrenoceptors were used to investigate the pharmacology of mAb3 in intact cellular systems. These were cells stably expressing either a C-terminal truncated wild-type turkey b-adrenoceptor (tbtrunc; [31] ) or a variant containing m23 thermo-stabilising mutations (tb6-m23; [30] ). The binding of mAb3 resulted in a concentration-dependent attenuation of the specific binding of [ 3 H]-CGP 12177 to both tb 1 -ARs. Applying an allosteric ternary complex model to these data enabled an estimate of the affinity of mAb3 for both the low expressing tbtrunc and high expressing tb6-m23 receptors to be determined. This did not significantly differ between the two tb 1 -AR variants (the dissociation constant K B was circa 20-25 nM in both cell lines). The primary sequences of the ECL2 in these two receptors are identical, implying that m23 mutations present in the tb6-m23 receptor did not significantly change the conformation of the ECL2. The cooperativity factor between mAb3 and [ 3 H]-CGP 12177 was also similar for the two tb 1 -ARs and indicated a high degree of negative cooperativity in both cases (Table 2 ). These data are consistent with a previous suggestion that mAb3 may behave as an allosteric modulator of [ 3 H]-dihydroalprenolol binding [28] .
The specific binding of mAb3 to CHO cells expressing b 1 -ARs was also visualised using immunocytochemistry. These data confirmed that mAb3 could selectively detect only tb 1 -adrenoceptors (both tbtrunc and tb6-m23 variants) in intact cells and was not able to bind to the human b 1 -adrenoceptor. It was also able to detect tbtrunc at very low expression levels (92 ± 14 fmol/mg protein) and mAb3 binding could be inhibited by a turkey ECL2 peptide, but not by the equivalent human ECL2 peptide.
The human ECL2 shares 70% homology with the Tk ECL2 (Fig. 4d) . The human b 1 -AR ECL2 primary sequence differs from the Tk ECL2 by only eight residues. Single point mutations of these turkey residues to their human equivalent did not affect the binding of mAb3 in cells transiently transfected with the relevant variant of the t b6-m23 receptor. All showed a 38-60% reduction on the specific binding of 0.5-2.5 nM CGP12177 to the t b6-m23 receptor. Interestingly, substitution of the full human ECL2 sequence in place of the turkey ECL2 in tb6-m23 showed the same effect as the triple mutant, suggesting that residues D186, P187 and Q188 are necessary for mAb3 binding. Mapping these residues to the b 1 AR-m23 StaR crystal structure (PDB ID: 2Y03; [39] ) indicate that the majority of these residues are located on the extracellular facing surface of the ECL2 (Fig. 4) . It is worth pointing, however, that mutation the three Table 3 Log EC 50 values, concentration ratios, relative activity, and E max as a percentage of 10 lM isoprenaline-stimulated CRE-SPAP production in CHO tbtrunc or tb6-m23 CRE-SPAP cells. Cells were treated with isoprenaline in combination with differing concentrations of mAb3 for five hours. Concentration ratios were determined by dividing the EC 50 in the presence of mAb3 from that in its absence. Relative activity represents the effect mAb3 has on the potency and efficacy of isoprenaline, and was derived as described under Methods. Data for each condition are mean ± s.e.m. from five individual experiments performed in triplicate. To gain some insight into the percentage of receptors occupied by mAb3 at the concentrations used in the present study, we have used a NanoBRET binding assay [43] . Using a similar approach to that we have previously reported in HEK 293 cells to study human b 1 -and b 2 -adrenoceptors [29, 43] , we demonstrated that a fluorescent analogue of CGP 12177 (CGP-12177-TMR) could be used to monitor the effect of mAb3 on the K D and maximal specific binding capacity of CGP-12177-TMR to an N-terminal NanoLuc-tagged variant of the tb6-m23 receptor. These data showed a similar 40% reduction in maximal specific binding in the presence of 200 nM mAb3 without any significant effect on the affinity of CGP-12177-TMR. NanoBRET was also used to monitor directly the affinity of mAb3 for NL-tb6-m23 expressed in HEK 293 cells using NanoBRET between a rhodamine-labelled secondary antibody to mAb3 and the extracellular Nanoluc of NL-tb6-m23. The affinity of mAb3 measured at the NL-tb6-m23 receptor (K D 17.8 nM) was very similar to that (19.5 nM) estimated from radioligand binding studies at the tb6-m23. The large size of the mAb3-secondary antibody complex does, however, mean that we can only conclude that the rhodamine on the secondary antibody was in close proximity (<10 nm) to the NanoLuc of a neighbouring b 1 -adrenoceptor rather than definitively conclude that it is to the b 1 -adrenoceptor to which mAb3 was bound. Notwithstanding these uncertainties, we can conclude that the occupancy achieved at the turkey b 1 -adrenoceptor with 200 nM and 1 mM mAb3 was very high (92 and 98% respectively).
Taken together, these data suggest that mAb3 binds to ECL2 of the turkey b 1 -adrenoceptor and acts allosterically to prevent the binding of orthosteric ligands to a subset (circa 40%) of b 1 -receptors present in the cells. The interaction of mAb3 with ECL2 and its consequent allosteric effects are consistent with the important role that ECL2 appears to have in ligand recognition [17] [18] [19] and as a site of allosteric modulation for other GPCRs [20, 21] . Furthermore, the structure and position of the ECL2 is known to be critical for receptor activation [22, 23] . To investigate the functional impact of mAb3 in stable CHO cell lines expressing the tbtrunc or tb6-m23 variants of the turkey b 1 -adrenoceptor we also investigated their signalling characteristics. We found no evidence that mAb3 was able to stimulate cAMP accumulation or downstream cAMP response element reporter gene responses. This contrasts with previous data on mAb3 in transiently transfected cells, where a small cAMP response was reported [28] . This is most likely due to the very high expression levels achieved with transient transfection. It has been documented previously that high receptor density can reveal partial agonist behaviour of ligands previously characterised as antagonists [47, 48] . MAb3 was, however, able to antagonise isoprenaline-mediated activation of the two tb 1 -ARs. This was evident both at the level of cAMP accumulation and a downstream reporter gene transcription. Schild analysis was consistent with a non-competitive interaction between mAb3 and isoprenaline at the tb6-m23 receptor. The reduction in the number of available receptors in the presence of mAb3 (detected from binding studies with both [ 3 H]-CGP 12177 and the fluorescent analogue of CGP 12177) that can bind agonist almost certainly explains the effect on signalling. Thus, the shift of the concentration-response curve to isoprenaline to higher agonist concentrations produced by mAb3 can be explained by: (a) the reduced receptor number and (b) the ability of the receptor reserve (due to signalling amplification) to enable maximal functional responses to isoprenaline to be achieved following a reduction in the receptor population. The data obtained with mAb3 are consistent with an allosteric effect. However, it is also possible that the interaction of a bulky monoclonal antibody with ECL2 might restrict access of agonists and antagonists to (or from) the orthosteric binding site deep within the transmembrane regions of the b 1 -adrenoceptor [8, 39] , due to a steric hindrance effect.
To investigate this possibility, the temporal profile of the changes in intracellular cAMP levels was monitored following sequential addition of isoprenaline and mAb3 or CGP 20712A. Addition of CGP 20712A, after intracellular cAMP levels had reached an equilibrium level following initial addition of isoprenaline, led to a rapid fall in cellular cAMP levels. This was due to the continuous binding and dissociation of isoprenaline that occurs when equilibrium is reached, and the rapid occupancy of vacant orthosteric binding sites that occurs when a high concentration of the competitive antagonist CGP 20712A is subsequently added. Addition of mAb3 led to a slower fall in cAMP levels that is consistent with a negative allosteric interaction. In the absence of mAb3 or CGP 20712A, cAMP levels were maintained for 60 min. Simultaneous addition of mAb3 and CGP 20712A provided the same rapid fall in cAMP to that obtained with CGP 20712A alone. These data indicate that mAb3 did not reduce access of CGP 20712A to, or isoprenaline from, the orthosteric binding site. This was confirmed when mAb3 was added first, to establish a slow fall in intracellular cAMP, and then subsequent addition of CGP 20712A created a rapid fall in cAMP levels.
It is very clear is that at the highest concentration of mAb3 used, the allosteric effect of the antibody on [ 12177 specific binding sites is consistent with mAb3 only interfering with a specific conformation/sub-population of the b1-ARs. The effect of mAb3 on b 1 -AR signalling suggests that the conformation/ sub-population of b 1 -AR targeted by the antibody is involved in Gs-mediated agonist action. However, it remains to be established whether this conformation (sensitive to inhibition by mAb3) represents the Gs-coupled b 1 -AR conformation. In summary, the data obtained in the present study suggest that mAb3 interacts with ELC2 to produce a pronounced negative allosteric effect on the binding of orthosteric ligands to a subset of turkey b 1 -adrenoceptors. It also elicited a negative allosteric effect on functional Gs-mediated responses. The identity of the subset of turkey b 1 -adrenoceptors influenced by mAb3 remains to be established. It is well known that GPCRs can exist in a spectrum of conformations, ranging from resting R and active R⁄ states to oligomeric complexes involving G protein, b-arrestin, scaffolding proteins [49, 50] and multiple GPCR molecules [51] . These conformations have the potential to be selectively targeted by antibodies. For example, single-domain camelid immunoglobulins (termed nanobodies) have been utilised to recognise and stabilise active (Nb80; [9, 52, 53] ) and inactive (Nb60; [53] ) conformations of the b 2 -adrenoceptor.
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